HDAC
Histone deacetylases (HDACs), known for their ability to target histones as well as more than 50 non-histone proteins, are classified into three major classes according to their homology to yeast proteins, including class I (HDAC1, HDAC2, HDAC3 and HDAC8), class II (HDAC4, HDAC5, HDAC7 and HDAC9) and class IV (HDAC11). HDAC inhibitors, a large group of compounds that is able to induce the accumulation of acetylated histones as well as non-histone proteins, are divided into several structural classes including hydroxamates, cyclic peptides, aliphatic acids and benzamides. HDAC inhibitors have been investigated for their efficacy as anticancer agents in the treatment of a wild range of cancers.
- B1251 Valproic acidTarget: Histone Deacetylases (HDACs)Summary: HDAC1 inhibitor
- B4890 HPOB1 CitationTarget: Histone Deacetylases (HDACs)Summary: HDAC6 inhibitor, potent and selective
- B5916 Chidamide1 CitationTarget: HDACSummary: Novel HDAC inhibitor
- B5936 ACY-241Summary: Selective and orally active HDAC6 inhibitor
- B5949 BG45Summary: Novel HDAC3-selective inhibitor
- B5967 UF 010Summary: Novel and selective class I HDAC inhibitor
- B5968 BML-210(CAY10433)Summary: Novel HDAC inhibitor
- B5969 2-hexyl-4-Pentynoic AcidSummary: Potent and robust HDACs inhibitor
- B7816 ITSA-1 (ITSA1)Summary: HDAC activator via Trichostatin A (TSA) suppression
- C4018 4-iodo-SAHASummary: class I and class II histone deacetylase (HDAC) inhibitor